According to Immunocore's CEO, the biggest imminent shift in drug development is AI. The critical need is not for AI to replace scientists, but for a new breed of professionals fluent in both their scientific domain and artificial intelligence. Those who fail to adapt will be left behind.

Related Insights

The most potent productivity gains from AI aren't just for junior staff. Seasoned professionals who combine deep domain expertise with adaptability are using AI to rapidly learn adjacent skills like design or marketing. This allows them to "collapse the skill stack" and single-handedly perform tasks that previously required multiple people.

Instead of choosing a career based on its perceived "safety" from AI, individuals should pursue their passions to quickly become domain experts. AI tools augment this expertise, increasing the value of experienced professionals who can handle complex, nuanced situations that AI cannot.

Industry leaders from LinkedIn and Salesforce predict that AI will automate narrow, specialized tasks, fundamentally reshaping careers. The future workforce will favor 'professional generalists' who can move fluidly between projects and roles, replacing rigid departmental structures with dynamic 'work charts.'

As AI agents handle technical execution, the most valuable human skill becomes ideation. Replit CEO Amjad Massad predicts this will dissolve rigid corporate hierarchies in favor of adaptable teams of generalists who collaborate with autonomous AI tools to bring ideas to life.

AI lowers the economic bar for building software, increasing the total market for development. Companies will need more high-leverage engineers to compete, creating a schism between those who adopt AI tools and those who fall behind and become obsolete.

By selecting AI researcher Alex Reeves to head its science program, CZI is signaling a fundamental belief: AI is no longer just a tool for biology but is now the primary driver of discovery. Leadership must reflect this shift from a biology-first to an AI-led approach.

AI will create jobs in unexpected places. As AI accelerates the discovery of new drugs and medical treatments, the bottleneck will shift to human-centric validation. This will lead to significant job growth in the biomedical sector, particularly in roles related to managing and conducting clinical trials.

The rise of AI tools isn't replacing the PM role, but transforming it. PMs who embrace an "AI-enhanced" workflow for research, docs, and prototyping will gain a massive productivity advantage, ultimately displacing those who stick to traditional methods.

AI will handle most routine tasks, reducing the number of average 'doers'. Those remaining will be either the absolute best in their craft or individuals leveraging AI for superhuman productivity. Everyone else must shift to 'director' roles, focusing on strategy, orchestration, and interpreting AI output.

Contrary to fears of displacement, AI tools like 'AI co-scientists' amplify human ingenuity. By solving foundational problems (like protein folding) and automating tedious tasks, AI enables more researchers, even junior ones, to tackle more complex, high-level scientific challenges, accelerating discovery.